Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

39results about How to "Reduce cell proliferation" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Micrornas differentially expressed in pancreatic diseases and uses thereof

InactiveUS20090131348A1Reduce cell proliferationIncrease and decreasing cell proliferationOrganic active ingredientsAntipyreticDiseasePancreatic disease

The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.

Micrornas differentially expressed in pancreatic diseases and uses thereof

View all

Owner:INTERPACE DIAGNOSTICS LLC

Novel tricyclic protein kinase modulators

InactiveUS20110071136A1Good treatment effectReduce cell proliferationBiocideSenses disorderInflammationImmunologic disease

The invention provides compounds that inhibit CK2 and / or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.

Novel tricyclic protein kinase modulators

View all

Owner:SENHWA BIOSCIENCES INC

Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor

InactiveUS20070066616A1Inhibit cell proliferationReduce cell proliferationBiocideAnimal repellantsExtracellular signalComputer aid

Provided herein are compounds and methods of using compounds that selectively inhibit binding to one or more docking domain regions of an extracellular signal-regulated kinase (ERK) to inhibit in a cell having an extracellular signal-regulated kinase activity. Such methods may be used to inhibit cell proliferation of a neoplastic cell, to treat a cancer and further may be used in conjunction with administration of an anticancer drug at a reduced dosage to treat a cancer with a concomitant reduction in toxicity to an individual receiving the treatment. Also provided is a method to design and screen for compounds to inhibit binding within the extracellular signal-regulated kinase docking domain region, using at least in part computer-aided drug design modeling.

Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor

View all

Owner:SHAPIRO PAUL +1

Formulations for the treatment of arthritis conditions

InactiveUS20060280811A1Reduce cell proliferationStimulate proteoglycan synthesisBiocideNervous disorderBeta-boswellic acidGluconic acid

The present invention relates to formulations comprising combinations of analgesic / anti-inflammatory, immunomodulating and cartilage-reconstructing agents in particular comprising saligenig, boswellic acid, procyanidins, N-acety-glucosamine and either glucoronic acid or glucoronolactone, for the treatment of rheumatoid arthritis and, more generally, of arthritis conditions.

Owner:INDENA SPA

Dimeric Smac Mimetics

InactiveUS20110195043A1Reduce cell deathReduce cell proliferationAntipyreticAnalgesicsSmac mimeticsDisease

The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.

View all

Owner:JOYANT PHARMA INC

Lymphocytes; methods

InactiveUS20050048054A1Reduce cell proliferationIncreasing cell proliferationImmunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against cell receptors/antigens/surface-determinantsRegulatory T cellLymphocyte

Provided are methods of modulating activity of regulatory T cells, CD4+ T cells, and CD8+ T cells. Also provided are methods of treating immune disorders.

Owner:SCHERING CORP

Combination therapy of cancer with Anti-endoglin antibodies and Anti-vegf agents

InactiveUS20120244147A1Improve the situationImprove survivalSenses disorderAntipyreticEndoglinBevacizumab Injection

The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

Combination therapy of cancer with Anti-endoglin antibodies and Anti-vegf agents

View all

Owner:HEALTH RES INC +1

Antagonistic Anti-tumor necrosis factor receptor superfamily antibodies

ActiveUS20180194850A1Inhibit and reduce proliferationPromote apoptosisPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegulatory T cellTnfr superfamily

Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

Antagonistic Anti-tumor necrosis factor receptor superfamily antibodies

View all

Owner:THE GENERAL HOSPITAL CORP

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

ActiveUS20140163090A1Reduced neoplastic progenitor cell proliferationReduce cell proliferationPowder deliveryGenetic material ingredientsProliferative diseaseWilms' tumor

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

View all

Owner:GERON CORPORATION

Methods of Using IGFIR and ABL Kinase Modulators

InactiveUS20090232828A1Reduce cell proliferationBiocideOrganic chemistrySurgery radiationChemotherapeutic drugs

The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).

Methods of Using IGFIR and ABL Kinase Modulators

View all

Owner:EXELIXIS INC

Monoclonal antibodies to human thymidine kinase to treat cancer

ActiveUS20100143244A1Good effectReduce cell proliferationUltrasonic/sonic/infrasonic diagnosticsSurgeryApoptosisComplete antibody

A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.

Monoclonal antibodies to human thymidine kinase to treat cancer

View all

Owner:SAVOY PHARMA

Methods and Compositions for the Inhibition of Gene Expression

InactiveUS20110135710A1Reduce cell proliferationReduce spreadMicroencapsulation basedCarbohydrate active ingredientsOligonucleotideGene expression

The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.

View all

Owner:PRONAI THERAPEUTICS INC

Annexin a11 and associated genes as biomarkers for cancer

InactiveUS20120004289A1Reduce cell proliferationReduced colony formation abilityOrganic active ingredientsGenetic material ingredientsAnnexin A1Biomarker (petroleum)

The instant invention provides methods and compositions for the diagnosis and treatment of cancer. The invention also provides method and compositions for determining if a subject is, or is at risk of becoming, chemoresistant.

Annexin a11 and associated genes as biomarkers for cancer

View all

Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Anticancer therapeutic agents

InactiveUS20130345231A1Reduce cell proliferationGood treatment effectBiocideAnimal repellantsNon malignantCytotoxicity

The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.

View all

Owner:INDIANA UNIV RES & TECH CORP

Inhibition of dynamin related protein 1 to promote cell death

ActiveUS20150017262A1Reduce cell proliferationPromote cell deathHeavy metal active ingredientsBiocideDNA injuryCancer research

The present invention relates to compositions and methods for reducing cell proliferation and / or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp1 inhibition results in a disruption of the cell cycle and DNA aberrancies; (ii) inhibition of both Drp1 and ATR are synthetic lethal causing increased DNA damage and apoptotic cell death; and (iii) even in resistant cell lines, Drp1 inhibitor (e.g., mdivi-1) together with a second antiproliferative agent (e.g., cisplatin or carboplatin) act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies.

Inhibition of dynamin related protein 1 to promote cell death

View all

Owner:UNIVERSITY OF PITTSBURGH

Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

ActiveUS20140155465A1Reduce cell proliferationSpeed upGenetic material ingredientsMicrobiological testing/measurementTelomeraseCancer research

Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds.

Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

View all

Owner:GERON CORPORATION

Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer

InactiveUS20130149320A1Reduce cell proliferationPoor outcomeOrganic active ingredientsPeptide/protein ingredientsHuman cancerAdjuvant therapy

The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for treating cancer.

Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer

View all

Owner:INSTITUT CURIE +1

Recombinant ubiquitin ligase PTB-U-box fusion gene and expression vector and application thereof

ActiveCN102174550APromote degradationReduce cell proliferationGenetic material ingredientsFermentationNucleotideNucleotide sequencing

The invention discloses a recombinant ubiquitin ligase PTB-U-box fusion gene and an expression vector and application thereof. The recombinant ubiquitin ligase PTB-U-box fusion gene is formed by connecting a PTB domain gene of IRS-1 and a U-box domain gene of carboxy terminus of Hsc70 Interacting protein (CHIP), and the specific nucleotide sequence is shown as SEQ ID No. 1. The constructed PTB-U-box fusion gene can be cloned to different expression vectors so as to enter tumor cells through different paths to play a role, and the expression vectors comprise eukaryotic expression vectors or adenovirus expression vectors. After the fusion gene transfects the tumor cells, the carcinogenic related protein IGF-1R of the host tumor cells can be regulated down, the cell proliferation and intrusion capacities of the tumor cells are remarkably reduced, and the fusion gene shows proliferation inhibition and intrusion inhibition on the tumor cells so as to achieve the anti-tumor effect.

Recombinant ubiquitin ligase PTB-U-box fusion gene and expression vector and application thereof

View all

Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Nanoparticle delivery systems for membrane-integrating peptides

InactiveUS20080274056A1Reduce cell proliferationFacilitated releaseAntibacterial agentsPowder deliveryLipid formationEmulsion

Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid / surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described.

Nanoparticle delivery systems for membrane-integrating peptides

View all

Owner:WASHINGTON UNIV IN SAINT LOUIS

Cannabinoid drugs

InactiveUS6914072B2Reduce cell proliferationReduce proliferationBiocideOrganic chemistryCannabinoidTetrahydrocannabinol

The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.

View all

Owner:ATLANTIC TECH VENTURES +1

Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms

InactiveUS20150342982A1Reduced neoplastic progenitor cell proliferationReduce cell proliferationOrganic active ingredientsTransferasesTelomeraseBlood platelet counts

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorders, such as ET.

View all

Owner:GERON CORPORATION

Frmd4a antagonists and their uses

InactiveUS20140023589A1Reduce the overall heightImprove survivalOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsFERM domainAdenocarcinoma

An antagonist of FERM domain-containing protein 4A (FRMD4A) and / or of the Hippo pathway for use in a method of treating a cancer in a mammalian subject, wherein the cancer is selected from: squamous cell carcinoma (SCC), an epithelial cancer, an adenocarcinoma and a carcinoma is disclosed, as well as related methods of treatment of cancer, methods of screening and generating such antagonists, including anti-FRMD4A antibodies.

View all

Owner:CANCER RES TECH LTD

Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer

InactiveUS7267977B2Inhibit bindingReduce functionBacteriaGenetic material ingredientsSubcellular localizationPeripheral-Type Benzodiazepine Receptor

The expression and subcellular localization of peripheral-type benzodiazepine receptors (PBR) is shown in this application to correlate with the metastatic potential of cells, and increased cell proliferation. Inhibition of PBR expression, function or stability results in a decrease in cell proliferation. Compositions and methods for regulating and / or monitoring PBR and its expression are useful for the detection, diagnosis, prognosis and treatment of solid tumors, in particular, breast cancer.

Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer

View all

Owner:GEORGETOWN UNIV

Novel protein kinase modulators

InactiveUS20110065698A1Good treatment effectReduce cell proliferationAntibacterial agentsBiocideFms-Like Tyrosine KinaseDrug biological activity

The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and / or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.

View all

Owner:SENHWA BIOSCIENCES INC

Azithromycin derivatives containing a phosphonium ion as anticancer agents

ActiveUS20210261582A1Preventing increase in “ stage ”Avoid developmentSugar derivativesGroup 5/15 element organic compoundsAnticarcinogenPhosphonium

This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds.

Azithromycin derivatives containing a phosphonium ion as anticancer agents

View all

Owner:RISING TIDE FOUND

Tissue Inhibitor of Metalloproteinases (Timp) Linked to Glycosylphosphatidylinositol (Gpi) - Anchors for Treatment of Cancer and Skin Lesions

InactiveUS20110105407A1Promotes fibroblast differentiationDecrease in ECM turnoverPeptide/protein ingredientsProtease inhibitorsAnticarcinogenTissue inhibitor of metalloproteinase

The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual.

Tissue Inhibitor of Metalloproteinases (Timp) Linked to Glycosylphosphatidylinositol (Gpi) - Anchors for Treatment of Cancer and Skin Lesions

View all

Owner:NELSON

Crystalline composition of GM-CSF/GM-CSFR

InactiveUS8489339B2Reduce tyrosine phosphorylationReduce cell proliferationAntipyreticAnalgesicsGranulocyte macrophage colony-stimulating factorBiology

The present invention relates generally to the field of crystallography. More particularly, the present invention provides crystalline forms of a complex between granulocyte macrophage-colony stimulating factor (GM-CSF) and its receptor (GM-CSFR). The present invention further provides methods for the design and selection of modulators of GM-CSF / GM-CSFR interaction and signaling as well as signaling of other cytokines.